文献速递造血干细胞移植与细胞治疗

纯化供者CD34阳性细胞输注治疗异基因移植后移植物功能不良的回顾性队列研究

[CD34(+) selected donor hematopoietic stem cell infusion for poor graft function after allogeneic hematopoietic stem cell transplantation: a retrospective cohort study].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

该回顾性队列研究纳入25例异基因造血干细胞移植后发生移植物功能不良的患者,采用免疫磁珠分选供者CD34阳性细胞进行治疗性输注。结果显示中性粒细胞和血小板植入不良的恢复率分别为80.0%和71.4%,GVHD发生率仅12.0%,总生存率为(65.63±8.28)%,提示该疗法安全有效。

要点

  • 纯化供者CD34阳性细胞输注可改善移植后移植物功能不良。
  • 中性粒细胞和血小板恢复率分别为80.0%和71.4%。
  • GVHD发生率低(12.0%),主要为轻度。

核心结论

  • 免疫磁珠分选CD34阳性细胞效果良好,纯化后输注可安全有效地改善异基因造血干细胞移植后移植物功能不良。

研究设计与样本

  • 回顾性队列研究,纳入2019年9月至2023年3月中国医学科学院血液病医院25例移植后移植物功能不良患者,其中半相合19例、全相合6例。

主要发现

  • 分选前CD34阳性细胞总数中位值为2.64(0.82-6.53)×10^8,分选后为2.22(0.48-5.68)×10^8,中位回收率78.37%(58.48%-115.72%)。
  • 10例中性粒细胞植入不良患者中8例(80.0%)恢复,中性粒细胞绝对计数≥0.5×10^9/L,中位恢复时间21(10-40)天。
  • 21例血小板植入不良患者中15例(71.4%)恢复,血小板计数≥20×10^9/L,中位恢复时间15(13-38)天。
  • 输注后仅3例(12.0%)发生GVHD,包括2例Ⅰ度急性GVHD和1例局限性慢性GVHD。
  • 中位随访14.47(0.23-41.63)个月,输注后总生存率为(65.63±8.28)%,17例存活,中位生存时间19.07(0.23-41.63)个月。

临床怎么用

  • 对于异基因造血干细胞移植后发生移植物功能不良的患者,可考虑供者CD34阳性细胞分选后输注以促进造血恢复。

局限性

  • 回顾性研究,样本量较小(25例),随访时间有限,结论需进一步前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy of purified donor CD34 positive hematopoietic stem cell (CD34(+) cell) infusion in patients with poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: The clinical data of 25 patients with PGF who underwent donor CD34(+) cell sorting and infusion at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences between September 2019 and March 2023, were retrospectively analyzed. The cohort included 19 haploidentical and 6 HLA-matched cases. CD34(+) cells were purified using immunomagnetic beads for therapeutic infusion. The purification efficiency was evaluated based on the purity and recovery rate of CD34(+) cells. Clinical outcomes were assessed by hematopoietic recovery, overall survival (OS) rate, and the incidence of graft-versus-host disease (GVHD) . Results: The median total number of CD34(+) cells was 2.64 (0.82-6.53) × 10(8) before purification and 2.22 (0.48-5.68) ×10(8) after purification, with a median recovery rate of 78.37% (58.48%-115.72%) . After infusion of purified CD34(+) cells, 8 of 10 patients (80.0%) with poor neutrophil engraftment achieved recovery (absolute neutrophil count ≥ 0.5×10(9)/L) , with a median time to recovery of 21 (10-40) days. And 15 of 21 patients (71.4%) with poor platelet engraftment achieved recovery (platelet count ≥ 20×10(9)/L) , with a median time to recovery of 15 (13-38) days. Only 3 patients (12.0%) developed GVHD after the infusion of purified CD34(+) cells, including 2 cases of grade I acute GVHD and 1 case of limited chronic GVHD. With a median follow-up of 14.47 (0.23-41.63) months, the overall OS rate after CD34(+) cell infusion was (65.63± 8.28) %. Seventeen patients survived, with a median survival time of 19.07 (0.23-41.63) months. Conclusion: Purification of CD34(+) cells using immunomagnetic beads is effective, and the infusion of these purified donor CD34(+) cells can safely and effectively improve PGF after allo-HSCT. 目的: 分析纯化供者外周血CD34阳性造血干细胞(以下简写为CD34(+)细胞)输注对异基因造血干细胞移植(allo-HSCT)后发生移植物功能不良(PGF)患者的疗效。 方法: 回顾性分析2019年9月至2023年3月期间在中国医学科学院血液病医院进行供者CD34(+)细胞分选并输注治疗的25例发生PGF患者的临床资料,其中半相合19例,全相合6例。利用免疫磁珠的方法分选纯化CD34(+)细胞用于患者的治疗性输注,以CD34(+)细胞的阳性率和回收率来分析纯化的效果,患者预后情况以造血恢复、总生存(OS)率以及移植物抗宿主病(GVHD)发生等指标进行分析。 结果: 分选纯化前后的CD34(+)细胞总数的中位值分别为2.64(0.82~6.53)×10(8)个和2.22(0.48~5.68)×10(8)个,中位回收率为78.37(58.48~115.72)%。纯化CD34(+)细胞输注后,10例中性粒细胞植入不良的患者中8例(80.0%)恢复(中性粒细胞绝对计数≥0.5×10(9)/L),中位恢复时间为21(10~40)d,21例血小板植入不良的患者中15例(71.4%)恢复(血小板计数≥20×10(9)/L),中位恢复时间为15(13~38)d。与输注前相比,仅3例(12.0%)患者在输注纯化CD34(+)细胞后发生GVHD,其中Ⅰ度急性GVHD 2例,局限性慢性GVHD 1例。中位随访14.47(0.23~41.63)个月,患者总体CD34(+)细胞输注后的OS率为(65.63±8.28)%,输注后17例患者存活,中位生存时间为19.07(0.23~41.63)个月。 结论: 利用免疫磁珠方法进行CD34(+)细胞纯化分选的效果良好,纯化的供者CD34(+)细胞输注可安全、有效地改善allo-HSCT后发生的PGF。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu S, Li Q, Liu ZY, et al. [CD34(+) selected donor hematopoietic stem cell infusion for poor graft function after allogeneic hematopoietic stem cell transplantation: a retrospective cohort study]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41339045. doi:10.3760/cma.j.cn121090-20241120-00460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。